1. Long-term treatment with fibrates and ursodeoxycholic acid in people with Primary Sclerosing Cholangitis is safe and associated with persistent clinical and biochemical improvement. (March 2023) Authors: Catanzaro, E.; Peviani, M.; Perin, N.; Bonaiuto, E.; Simionato, F.; Motta, R.; Gambato, M.; Floreani, A.; Cazzagon, N. Journal: Digestive and liver disease Issue: Volume 55(2023)Supplement 1 Page Start: S59 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. People with autoimmune hepatitis and celiac disease have a milder liver disease course and a better chance of immunosuppressive treatment withdrawal. (March 2023) Authors: Pezzato, F.; D'Ovidio, E.; Perini, L.; Bonaiuto, E.; Rollo, P.; Catanzaro, E.; Peviani, M.; Russo, F.P.; D'Odorico, A.; Zingone, F.; Floreani, A.; Cazzagon, N. Journal: Digestive and liver disease Issue: Volume 55(2023)Supplement 1 Page Start: S63 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Recurrence of primary sclerosing cholangitis after liver transplantation: A single center data. (March 2023) Authors: Catanzaro, E.; Cazzagon, N.; Floreani, A.; Senzolo, M.; Germani, G.; Zanetto, A.; Russo, F.P.; Gringeri, E.; Cillo, U.; Burra, P.; Gambato, M. Journal: Digestive and liver disease Issue: Volume 55(2023)Supplement 1 Page Start: S60 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗